{
    "url_original": "https://www.wsj.com/articles/eli-lilly-profit-rises-helped-by-covid-19-drug-sales-11611926977?mod=business_featst_pos3",
    "url": "eli-lilly-profit-rises-helped-by-covid-19-drug-sales-11611926977",
    "title": "Eli Lilly Profit Rises, Helped by Covid-19 Drug Sales",
    "sub_head": "Antibody drug bamlanivimab brought in world-wide revenue of $871.2 million, contributing much of the company’s 22% quarterly revenue growth",
    "category_1": "Business",
    "time": "2021-01-29 08:47:00",
    "body": "Eli Lilly and Co. reported a 41% rise in its quarterly profit on Friday, boosted by strong sales of its Covid-19 antibody treatment and higher demand for its diabetes drugs.<br />The antibody drug, bamlanivimab, brought in world-wide revenue of $871.2 million, contributing much of the 22% revenue growth the company recorded for the fourth quarter of 2020.<br />The company’s profit jumped to $2.12 billion, or $2.32 a share, compared with $1.5 billion, or $1.64 a share, in the same quarter a year earlier.<br />Eli Lilly shares rose 4.7% in pre-market trading after closing Thursday at $210.12. The company’s stock has moved higher in the second half of January as studies have shown promising results for its products aimed at treating and preventing Covid-19.<br />Bamlanivimab, which has been approved by the Food and Drug Administration on an emergency basis for treating mild to moderate Covid-19 in high-risk patients, complements vaccines while inoculations increase."
}